Zeta TLE1 Antibody. Zeta’s recombinant mouse antibody recognizes TLE1 (Transducin-like enhancer protein 1), a transcriptional repressor that plays a key role in neurogenesis, segmentation and sex determination. Key players in the Notch pathway are the TLE genes, which are human homologs of the Drosophila Groucho gene. Transducin-like enhancer protein 1 (TLE1) is a protein that is encoded by the TLE1 gene and is involved in control of hematopoiesis, neuronal, and terminal epithelial differentiation. Positive immunohistochemical nuclear staining with a TLE-1 antiody has been shown to be a useful addition to an IHC panel when differentiating synovial sarcoma from other soft tissue malignancies. TLE1 affects signaling pathways relating to embryogenesis, hematopoiesis and differentiation including lateral inhibition, segmentation, sex determination, eye development and neuronal differentiation. TLE1 modulates several signaling pathways, including the WNT and beta catenin pathway, NOTCH pathway and sonic hedgehog pathway.
TLE1 acts as either an oncogene or tumor suppressor in various cancer types. TLE1 immunohistochemical staining is most commonly used for nuclear staining in synovial sarcoma is a diagnostic consideration, which should be interpreted in the appropriate context of other histology and immunohistostaining results.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.